PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.39
5.09M / 4.21M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-30.55%
Negative revenue growth while JHX stands at 3.98%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-46.45%
Negative gross profit growth while JHX is at 13.15%. Joel Greenblatt would examine cost competitiveness or demand decline.
-97.89%
Negative EBIT growth while JHX is at 20.69%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-97.89%
Negative operating income growth while JHX is at 20.69%. Joel Greenblatt would press for urgent turnaround measures.
-88.18%
Negative net income growth while JHX stands at 93.86%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-88.32%
Negative EPS growth while JHX is at 89.47%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-88.32%
Negative diluted EPS growth while JHX is at 89.47%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-3.85%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-3.06%
Reduced diluted shares while JHX is at 0.17%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-135.43%
Negative OCF growth while JHX is at 43.76%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-181.94%
Negative FCF growth while JHX is at 299.03%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
9.79%
10Y revenue/share CAGR under 50% of JHX's 156.34%. Michael Burry would suspect a lasting competitive disadvantage.
9.79%
5Y revenue/share CAGR under 50% of JHX's 46.49%. Michael Burry would suspect a significant competitive gap or product weakness.
9.79%
3Y revenue/share CAGR under 50% of JHX's 52.82%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-14.61%
Negative 10Y OCF/share CAGR while JHX stands at 222.56%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-14.61%
Negative 5Y OCF/share CAGR while JHX is at 122.53%. Joel Greenblatt would question the firm’s operational model or cost structure.
-14.61%
Negative 3Y OCF/share CAGR while JHX stands at 33.74%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
547.47%
Net income/share CAGR above 1.5x JHX's 10.95% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
547.47%
5Y net income/share CAGR above 1.5x JHX's 74.05%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
547.47%
Below 50% of JHX's 1583.66%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
4.46%
Below 50% of JHX's 13323.16%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
4.46%
Below 50% of JHX's 94.68%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
4.46%
Below 50% of JHX's 60.53%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.46%
AR growth well above JHX's 6.68%. Michael Burry fears inflated revenue or higher default risk in the near future.
7.64%
We show growth while JHX is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-2.39%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-0.23%
We have a declining book value while JHX shows 6.76%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
7.87%
We have some new debt while JHX reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-12.59%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.